Market Perform Rating For Madrigal Pharmaceuticals (MDGL) At Raymond James.

June 29, 2018 - By Maria Fierro

What’s Raymond James’s Current Rate of Madrigal Pharmaceuticals (MDGL)

On 28 June, a coverage began with Madrigal Pharmaceuticals (MDGL) that has Market Perform rating at Raymond James, Octafinance.com reports.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Ratings Coverage

A total of 8 analysts rate Madrigal Pharmaceuticals (MDGL) as follows: 6 “Buy”, 2 “Hold” and 0 “Sell”. Тherefore 75% are bullish. (MDGL) has 12 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Tuesday, January 30 H.C. Wainwright maintained Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) rating. H.C. Wainwright has “Buy” rating and $156 target. On Tuesday, June 19 the firm has “In-Line” rating given by Evercore. On Monday, April 16 Oppenheimer initiated Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) with “Hold” rating. On Thursday, May 31 the firm earned “Buy” rating by Goldman Sachs. On Thursday, February 8 the rating was maintained by Evercore with “Outperform”. On Thursday, May 31 Oppenheimer upgraded Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) to “Buy” rating. On Friday, June 1 the stock of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has “Buy” rating given by H.C. Wainwright. On Friday, March 23 the stock has “Buy” rating by Goldman Sachs. In Friday, March 16 report Roth Capital maintained the stock with “Buy” rating. On Thursday, May 31 JMP Securities maintained Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) with “Buy” rating.

Ticker’s shares touched $281.62 during the last trading session after 1.32% change.Madrigal Pharmaceuticals, Inc. has volume of 39,703 shares. Since June 29, 2017 MDGL has risen 630.32% and is uptrending. MDGL outperformed by 617.75% the S&P500.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)’s earnings release is expected by WallStreet on August, 9, as reported by RTT. Analysts predict $-0.60 earnings per share, which is $0.09 up or 13.04 % from 2017’s $-0.69 earnings per share. After $-0.45 EPS report last quarter, Wall Street now sees 33.33 % negative EPS growth of Madrigal Pharmaceuticals, Inc..

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.The firm is worth $4.29 billion. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.Currently it has negative earnings. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials.

For more Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) news released recently go to: Benzinga.com, Globenewswire.com, Fool.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives” released on June 23, 2018, “Madrigal Pharmaceuticals Prices Public Offering of Common Stock” on June 07, 2018, “Are These Red-Hot NASH Stocks Still a Buy?” with a publish date: June 14, 2018, “Why Viking Therapeutics Stock Is On Fire Today” and the last “Premarket analyst action – healthcare” with publication date: June 19, 2018.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.